Does Smoking Status Predict Risk In Patients Undergoing Surgery for Head and Neck Cancer?
the Cancer Therapy Advisor take:
It is established that a patient’s use of tobacco puts them at risk for developing head and neck cancer. What is unknown, however, is the effect of tobacco use on postoperative outcomes.
Researchers recruited 89 patients with head and neck cancer before they underwent surgery and asked them to self identify as either never-smokers, former smokers, or current smokers. They were also assessed through a urinary cotinine for recent exposure to tobacco on the day of their surgery.
The outcomes recorded by the researchers included length of hospital stay and complications associated with surgery. There were 32.6% of patients who identified themselves as current smokers and 52.8% who identified as former smokers. The urinary cotinine assessment indicated 43.2% of patients as positive for recent tobacco exposure on the day of surgery.
Approximately 41% of patients experienced complications associated with their surgery. The mean length of stay was 4 days in patients who received low acuity procedures and 8.8 days in patients who received high acuity procedures.
The researchers found that patients who identified as a former smoker or a current smoker were more than 6 times more likely to experience a surgery-related complication than patients who identify as never having smoked (P=0.03).
Through this study, researchers were able to conclude that the use of tobacco during treatment may establish patients who are at a higher risk of complications related to surgery for head and neck cancer.
Tobacco increases risk for developing head and neck cancer, but the effect on postoperative outcomes is unknown.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Tool for Assessing Frailty Predicts Survival in Newly Diagnosed Multiple Myeloma
- Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Role of miR-125a-5p Clarified in Bladder Cancer
- Bladder Cancer Clinical Features Linked to EGFR and HER-2 Expression
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- A Vegan Diet and Cancer
- The Optimal Neoadjuvant Regimen of Checkpoint Inhibitors in High-Risk Melanoma Is Unclear